Biallelic Deletion of TNFRSF17 Associated With Resistance to BCMA-Targeting Therapies In Myeloma
OncLive,
Identifying BCMA expression, copy number variation, and point mutations can have important therapeutic implications for…
Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (M…
Overview of attention for article published in Journal of Clinical Oncology, June 2022
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (86th percentile)
-
Good Attention Score compared to outputs of the same age and source (71st percentile)
Readers on
- mendeley
- 29 Mendeley